Financial report context:
the company has a restricted stock plan for non-employee directors which reserves for issuance of 300000 shares of the company 2019s common stock . no restricted shares were issued in 2009 . the company has a directors 2019 deferral plan , which provides a means to defer director compensation , from time to time , on a deferred stock or cash basis . as of september 30 , 2009 , 86643 shares were held in trust , of which 4356 shares represented directors 2019 compensation in 2009 , in accordance with the provisions of the plan . under this plan , which is unfunded , directors have an unsecured contractual commitment from the company . the company also has a deferred compensation plan that allows certain highly-compensated employees , including executive officers , to defer salary , annual incentive awards and certain equity-based compensation . as of september 30 , 2009 , 557235 shares were issuable under this plan . note 16 2014 earnings per share the weighted average common shares used in the computations of basic and diluted earnings per share ( shares in thousands ) for the years ended september 30 were as follows: .

Financial table:
2009: average common shares outstanding; 2008: 240479; 2007: 244323; column_4: 244929
2009: dilutive share equivalents from share-based plans; 2008: 6319; 2007: 8358; column_4: 9881
2009: average common and common equivalent sharesoutstanding 2014 assuming dilution; 2008: 246798; 2007: 252681; column_4: 254810

Additional report context:
average common and common equivalent shares outstanding 2014 assuming dilution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246798 252681 254810 note 17 2014 segment data the company 2019s organizational structure is based upon its three principal business segments : bd medical ( 201cmedical 201d ) , bd diagnostics ( 201cdiagnostics 201d ) and bd biosciences ( 201cbiosciences 201d ) . the principal product lines in the medical segment include needles , syringes and intravenous catheters for medication delivery ; safety-engineered and auto-disable devices ; prefilled iv flush syringes ; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes ; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations ; surgical blades/scalpels and regional anesthesia needles and trays ; critical care monitoring devices ; ophthalmic surgical instruments ; and sharps disposal containers . the principal products and services in the diagnostics segment include integrated systems for specimen collection ; an extensive line of safety-engineered specimen blood collection products and systems ; plated media ; automated blood culturing systems ; molecular testing systems for sexually transmitted diseases and healthcare-associated infections ; microorganism identification and drug susceptibility systems ; liquid-based cytology systems for cervical cancer screening ; and rapid diagnostic assays . the principal product lines in the biosciences segment include fluorescence activated cell sorters and analyzers ; cell imaging systems ; monoclonal antibodies and kits for performing cell analysis ; reagent systems for life sciences research ; tools to aid in drug discovery and growth of tissue and cells ; cell culture media supplements for biopharmaceutical manufacturing ; and diagnostic assays . the company evaluates performance of its business segments based upon operating income . segment operating income represents revenues reduced by product costs and operating expenses . the company hedges against certain forecasted sales of u.s.-produced products sold outside the united states . gains and losses associated with these foreign currency translation hedges are reported in segment revenues based upon their proportionate share of these international sales of u.s.-produced products . becton , dickinson and company notes to consolidated financial statements 2014 ( continued ) .

Question: as of september 30 , 2009 what was the percent of the shares were held in trust that represented the directors 2019 compensation in accordance with the provisions of the plan .
Answer: 5%